Interleukins (ILs) are a group of cytokines (secreted proteins and signal molecules) that were first seen to be expressed by white blood cells (leukocytes). ILs can be divided into four major groups based on distinguishing structural features. However, their amino acid sequence similarity is rather weak (typically 15–25% identity). The human genome encodes more than 50 interleukins and related proteins.

Market Analysis and Insights: Global Recombinant Human Interleukin Market
The global Recombinant Human Interleukin market was valued at US$ XX in 2020 and will reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2022-2027.

Global Recombinant Human Interleukin Scope and Market Size
The global Recombinant Human Interleukin market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Interleukin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.

Segment by Type
IL-1
IL-2
IL-10
Others

Segment by Application
Medication
Scientific Research

The Recombinant Human Interleukin market is analysed and market size information is provided by regions (countries). Segment by Application, the Recombinant Human Interleukin market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.

By Company
Qilu Pharmaceutical
Hangzhou Jiuyuan
Merck and Co
Novartis Pharma
Abnova
Advanced Biotechnologies Inc
Cayman Chemical
Cell Signaling Technology
Thermo Fisher